Epithelioid Haemangioendothelioma Observational Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFondazione IRCCS Istituto Nazionale dei Tumori, Milano
About this trial
The EHE observational study was developed to obtain a high number of datas such as clinical presentation, natural history, and treatment outcomes, cto identificate cytokines and hormones as biomarkers and generate patient-derived preclinical models as a tool to assess the activity of anticancer agents and validate novel therapeutic targets
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histological diagnosis of EHE according to 2020 WHO classification, performed on biopsy or surgical specimen
Signed informed consent
Adequate patient compliance to treatment or follow up
No age limit
Disqualifiers
Impossibility to ensure adequate compliance
Trial population
We plan to include at least 50 patients (range: 50-70) in 36 months, followed by a follow up time of 3 years.68 including The Royal Marsden Hospital.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
50 Participants
are grouped into 5 trial groupsGroup A: Group A
Group B: Group B
Group C: Group C
Group D: Group D
Group E: Group E
Trial outcomes
Primary outcomes
1
Demographic description
To provide a demographic description of the population affected by advanced EHE
Time frame
Through study completion, an average of 1 year2
Patient status
To provide a description of clinical presentation, natural history, and treatment pattern in patients with advanced EHE
Time frame
Through study completion, an average of 1 year3
Tumor-related symptoms
To provide a description of tumour-related symptoms and their changes over time
Time frame
Through study completion, an average of 1 year4
Tumor-related pain
To provide a tumor-related pain assessment
Time frame
Through study completion, an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov